Citation only
via OpenAlex
Targeting mitochondrial dysfunction in neurodegenerative disease: Part I
Victoria Burchell, Sonia Gandhi, Emma Deas, Nicholas Wood, Andrey Y. Abramov, Hélène Plun‐Favreau
Expert Opinion on Therapeutic Targets · 2010 · ▲ 63 citations
Abstract
IMPORTANCE OF THE FIELD: The socioeconomic burden of an aging population has accelerated the urgency of novel therapeutic strategies for neurodegenerative disease. One possible approach is to target mitochondrial dysfunction(definition), which has been implicated in the pathogenesis of numerous neurodegenerative disorders. AREAS COVERED IN THIS REVIEW: This review examines the role of mitochondrial defects in aging and neurodegenerative disease, ranging from common diseases such as Alzheimer's and Parkinson's disease to rare familial disorders such as the spinocerebellar ataxias. The review is provided in two parts; in this first part, we discuss the mitochondrial defects that have been most extensively researched: oxidative stress; bioenergetic dysfunction and calcium deregulation. WHAT THE READER WILL GAIN: This review provides a comprehensive examination of mitochondrial defects observed in numerous neurodegenerative disorders, discussing therapies that have reached clinical trials and considering potential novel therapeutic strategies to target mitochondrial dysfunction. TAKE HOME MESSAGE: This is an important area of clinical research, with several novel therapeutics already in clinical trials and many more in preclinical stages. In part II of this review we will focus on possible novel approaches, looking at mitochondrial defects which have more recently been linked to neurodegeneration.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1517/14728221003652489
- Canonical
- link ↗
- Fetched
- 2026-06-06 MST
Cite this
APA
Burchell, V., Gandhi, S., Deas, E., Wood, N., Abramov, A.Y., & Plun‐Favreau, H. (2010). Targeting mitochondrial dysfunction in neurodegenerative disease: Part I. <em>Expert Opinion on Therapeutic Targets</em>. https://doi.org/10.1517/14728221003652489
Vancouver
Burchell V, Gandhi S, Deas E, Wood N, Abramov AY, Plun‐Favreau H. Targeting mitochondrial dysfunction in neurodegenerative disease: Part I. Expert Opinion on Therapeutic Targets. 2010. doi:10.1517/14728221003652489.
BibTeX
@article{victoria2010Target,
title = {Targeting mitochondrial dysfunction in neurodegenerative disease: Part I},
author = {Victoria Burchell and Sonia Gandhi and Emma Deas and Nicholas Wood and Andrey Y. Abramov and Hélène Plun‐Favreau},
journal = {Expert Opinion on Therapeutic Targets},
year = {2010},
doi = {10.1517/14728221003652489},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Current Neuropharmacology 2024
Preprint · CC-BY
Drug Target to Alleviate Mitochondrial Dysfunctions in Alzheimer’sDisease: Recent Advances and Therapeutic Implications
Biomedicines 2023
Open access · CC-BY
Mitochondria and Brain Disease: A Comprehensive Review of Pathological Mechanisms and Therapeutic Opportunities
Aging and Disease 2016
Open access · CC-BY
Mitochondrial Dysfunction in Alzheimer’s Disease and the Rationale for Bioenergetics Based Therapies
Neurotherapeutics 2023
Open access · CC-BY
Mitochondrial dysfunction in neurodegenerative disorders
Current Neurology and Neuroscience Reports 2018
Open access · CC-BY
Mitochondrial Dysfunction in Parkinson’s Disease: New Mechanistic Insights and Therapeutic Perspectives
Journal of Neurochemistry 2016
Open access · OA